Recruiting
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
NCT07516366· Phase 2· National Cancer Institute (NCI)· Source
Contact: Michael Daneshvar (principal investigator)
Recruiting
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
NCT07069699· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Nicole Foley (principal investigator)
Recruiting
Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation
NCT07615049· Phase 3· SWOG Cancer Research Network· Source
Contact: Jeremy P. Harris (principal investigator)
Recruiting
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
NCT07220187· Phase 3· SWOG Cancer Research Network· Source
Contact: Catherine C. Coombs (principal investigator)
Recruiting
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NCT07452458· Phase 3· NRG Oncology· Source
Contact: Xiao-Tang Kong (principal investigator)
Recruiting
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Xiao-Tang Kong (principal investigator)
Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT06980038· Phase 2· National Cancer Institute (NCI)· Source
Contact: Victoria M. Villaflor (principal investigator)
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source
Contact: Kelsey Edwards
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676· Phase 1/2· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc
Recruiting
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
NCT07195734· Phase 2· National Cancer Institute (NCI)· Source
Contact: Victoria M. Villaflor (principal investigator)
Recruiting
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Thuy Tran (principal investigator)
Recruiting
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07200830· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Omid Yazdanpanah (principal investigator)
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459· Phase 2· CatalYm GmbH· Source
Contact: Farshid Dayyani, Dr
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· Phase 3· NRG Oncology· Source
Contact: Caressa Hui (principal investigator)
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559· Phase 2· ALX Oncology Inc.· Source
Contact: Cheng Quah, MD
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544· Phase 3· National Cancer Institute (NCI)· Source
Contact: Nataliya Mar (principal investigator)
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012· Phase 1/2· Pfizer· Source
Recruiting
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
NCT06811116· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: April Choi (principal investigator)
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Erin H. Healy (principal investigator)
Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Contact: Maheswari Senthil (principal investigator)
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Shera Feinstein (principal investigator)
Active, not recruiting
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
NCT06730100· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: David S. Hong (principal investigator)
Recruiting
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
NCT06661915· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kiran Naqvi (principal investigator)
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131· Phase 3· UroGen Pharma Ltd.· Source
Contact: Edward Uchio
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916· Phase 1/2· Lantheus Medical Imaging· Source
Contact: Shyam Srinivas, MD, PhD
Recruiting
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06860594· Phase 1· National Cancer Institute (NCI)· Source
Contact: Jerica M. Lomax (principal investigator)
Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT07000084· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Michael Daneshvar (principal investigator)
Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT06724237· Phase 3· Eastern Cooperative Oncology Group· Source
Contact: Nicole Foley (principal investigator)
Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
NCT06577441· Phase 2· National Cancer Institute (NCI)· Source
Contact: Deepa Jeyakumar (principal investigator)
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· Phase 2· National Cancer Institute (NCI)· Source
Contact: Shera Feinstein (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Omid Yazdanpanah (principal investigator)
Recruiting
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
NCT06439836· Phase 1· National Cancer Institute (NCI)· Source
Contact: Nataliya Mar (principal investigator)
Recruiting
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
NCT06654037· Phase 1· National Cancer Institute (NCI)· Source
Contact: Farshid Dayyani (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Nataliya Mar (principal investigator)
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Sami Dwabe (principal investigator)
Recruiting
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
NCT06632977· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Rana McKay, MD
Recruiting
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Shirin Attarian (principal investigator)
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Elizabeth A. Brem (principal investigator)
Recruiting
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
NCT05687123· Phase 1· National Cancer Institute (NCI)· Source
Contact: Jennifer B. Valerin (principal investigator)
Active, not recruiting
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
NCT06169215· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180· Phase 3· Replimune, Inc.· Source
Contact: Thuy Tran, MD (principal investigator)
Recruiting
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939· Phase 3· SWOG Cancer Research Network· Source
Contact: Polina Bellman (principal investigator)
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Canadian Cancer Trials Group· Source
Contact: Jason A. Zell (principal investigator)
Recruiting
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
NCT05886049· Phase 1· National Cancer Institute (NCI)· Source
Contact: Kiran Naqvi (principal investigator)
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: Deepa Jeyakumar (principal investigator)
Recruiting
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT06102902· Phase 1· National Cancer Institute (NCI)· Source
Contact: Farshid Dayyani (principal investigator)
Showing 50 of 188.